MedPage Today

Humira Clobbers Biosimilars in Battle for Part D Coverage

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar ...

JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
WCBD

Adalimumab-adbm, Boehringer Ingelheim's Interchangeable biosimilar to Humira®, now available at low wholesale acquisition cost

RIDGEFIELD, Conn., Oct. 2, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that Adalimumab-adbm injection, the company's interchangeable* biosimilar to Humira ® (adalimumab), is now ...
Seeking Alpha

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...
Monthly Prescribing Reference

FDA Designates Yuflyma an Interchangeable Biosimilar to Humira

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
MedPage Today on MSN

Not All Drugs Approved for Rheumatoid Arthritis Are Equal for Pain Relief

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...
Nasdaq

Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira®

RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today a ...
Business Wire

REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator

JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is ...
Healio

FDA approves Abrilada as second interchangeable adalimumab biosimilar

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press ...
Healio

Adalimumab slashes Behçet’s uveitis relapse rate significantly more than cyclosporine

Please provide your email address to receive an email when new articles are posted on . Adalimumab plus corticosteroids significantly outperformed cyclosporine plus corticosteroids to delay Behçet’s ...
clinicaladvisor.com

Antidrug antibodies impact adalimumab treatment outcomes in psoriatic arthritis

Antidrug antibodies impact adalimumab treatment outcomes in psoriatic arthritis Determining the ideal blood serum level could translate to improved outcomes for patients with PsA. Undetectable levels ...